Teach me vortioxetine and ketamine-esketamine…introduction backgeound moa, phamacodynamics kinetics, uses, adr, contraindication, toxicity, abuse, discontinuation, guidelines for use, dosage formulation,indication,evidencebased trials,precaution, special population,drug interaction and eveyrthing related to it
Reading File
This is a very broad, comprehensive pharmacology question covering two major drugs. Let me search the medical library and PubMed in parallel for both drugs simultaneously.
Finding Sources
Finding Sources
Searching PubMed
vortioxetine depression efficacy
Searching PubMed
esketamine treatment-resistant depression
Good data found. Now let me read the detailed textbook sections for both drugs in parallel.
Reading File
Reading File
Excellent content found. Let me continue reading both drugs' sections for more detail on pharmacology, ADRs, dosing, and special populations.
Reading File
Reading File
I now have rich content from both drugs. Let me get more detail on pharmacokinetics and mechanisms, plus vortioxetine's specific section on cognition and the ketamine dosing/guidelines sections.
Reading File
Reading File
Excellent. I now have comprehensive data on both drugs. Let me get the remaining sections on ketamine's abuse potential, dosing guidelines, and the Maudsley prescribing guidelines section.
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me also get the Katzung pharmacology section and the Maudsley dosing table.
Reading File
Reading File
I now have very rich data. Let me update the todos and compile the comprehensive response.Here is the full comprehensive teaching guide on both drugs.
VORTIOXETINE (Trintellix) & KETAMINE/ESKETAMINE (Spravato) - Complete Pharmacology Guide
PART 1: VORTIOXETINE (Trintellix / Brintellix)
1. Introduction and Background
Vortioxetine was developed by Lundbeck with the deliberate aim of combining serotonin transporter (SERT) blockade with multiple serotonin receptor affinities - a "multimodal" approach. It was initially coded LU AA 21004. The first Phase II study was published in 2011, and it received FDA approval on September 30, 2013 for the treatment of major depressive disorder (MDD) in adults. It is marketed as Trintellix (formerly Brintellix, renamed to avoid confusion with the antiplatelet drug Brilinta).
-
Neuroscience-Based Nomenclature (NbN): Pharmacologic domain - Serotonin; Mechanism - Reuptake inhibitor (SERT), receptor partial agonist (5-HT1A), receptor antagonist (5-HT3)
-
Kaplan & Sadock's Comprehensive Textbook of Psychiatry
2. Chemistry
Vortioxetine is a piperazine derivative. Its full chemical name is 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine. Molecular weight: 298.4 g/mol.
3. Mechanism of Action (MOA)
Vortioxetine is unique among antidepressants because it simultaneously acts at multiple serotonin targets:
| Target | Action | Affinity (Ki) |
|---|---|---|
| SERT (5-HT transporter) | Reuptake inhibitor | 1.6 nM |
| 5-HT3 receptor | Antagonist | 3.7 nM |
| 5-HT7 receptor | Antagonist | 18 nM |
| 5-HT1A receptor | Full agonist | 15 nM |
| 5-HT1B receptor | Partial agonist | 33 nM |
| 5-HT1D receptor | Antagonist | 54 nM |
| NET (norepinephrine transporter) | Minimal affinity | 113 nM |
| DAT (dopamine transporter) | No significant affinity | >1,000 nM |
The net effect: SERT blockade increases synaptic 5-HT. The 5-HT3 antagonism disinhibits dopamine and norepinephrine release in prefrontal cortex. The 5-HT1A agonism provides anxiolytic effects and enhances neuroplasticity. The 5-HT7 antagonism may contribute to cognitive benefits and circadian rhythm regulation. This synergy produces greater downstream effects on multiple neurotransmitter systems (5-HT, DA, NE, acetylcholine) than SERT blockade alone.
PET occupancy data: 5-HT transporter occupancy reaches ~50% at 5 mg/day, ~65% at 10 mg/day, and ~80% at 20 mg/day. The lower occupancy at lower doses is thought to still be clinically meaningful due to synergistic receptor effects.
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Katzung's Basic and Clinical Pharmacology, 16th Ed.
4. Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | 75% (absolute), not affected by food |
| Tmax | 7-11 hours after oral dose |
| Protein binding | 98-99% |
| Volume of distribution | Extensive extravascular distribution |
| Half-life (t½) | ~66 hours (terminal) |
| Time to steady state | ~2 weeks |
| Metabolism | Primarily hepatic via CYP2D6; also CYP3A4/2C9 (minor) |
| Active metabolites | None - major metabolite (carboxylic acid) is pharmacologically inactive |
| Excretion | ~2/3 urine, ~1/3 feces (as metabolites); very little parent compound in urine |
| Cmax at 20 mg/day | 19.21 ng/mL; AUC = 361 ng·h/mL |
Key PK considerations:
-
In CYP2D6 poor metabolizers, plasma levels approximately double - halve the dose
-
CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion): increase levels - halve the dose
-
CYP inducers (e.g., rifampin, carbamazepine, phenytoin): decrease levels - may need to double dose (max 3x starting dose); when inducer stopped after >14 days co-administration, reduce back to original dose within 14 days
-
Strong CYP3A4/2C9 inhibitors: may further increase levels; use with caution
-
Vortioxetine itself does not inhibit or induce any major CYP isoenzymes and is not a P-glycoprotein substrate - low potential to cause drug interactions
-
Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Kaplan and Sadock's Synopsis of Psychiatry
5. Pharmacodynamics
The multimodal mechanism translates into several therapeutic advantages:
- Antidepressant effect - via SERT inhibition + receptor modulation
- Procognitive effects - particularly on attention, processing speed, and executive function (partially attributed to 5-HT3 and 5-HT7 antagonism which disinhibit acetylcholine and histamine release)
- Anxiolytic effects - via 5-HT1A agonism
- Better sexual tolerability than pure SSRIs in some patients (though sexual dysfunction still occurs)
- Lower propensity for weight gain and sedation than many other antidepressants
6. Indications
FDA-approved: MDD in adults (the ONLY currently approved indication).
Off-label / investigational rationale: The 5-HT1A agonist and SERT blocker properties provide a theoretical basis for use in anxiety disorders, OCD, PTSD, eating disorders, and PMDD - but the evidence base is currently insufficient to support these indications formally.
7. Dosage and Formulation
| Aspect | Detail |
|---|---|
| Available tablets | 5 mg, 10 mg, 20 mg |
| Starting dose | 10 mg/day (some patients start at 5 mg/day to improve GI tolerability) |
| Recommended dose range | 5-20 mg/day |
| Target/optimal dose | 20 mg/day (achieves ~80% SERT occupancy) |
| Administration | Once daily, morning (for convenience) or evening; no food restrictions |
| Titration | Can increase to 20 mg based on response/tolerability; if side effects problematic, can hold for 3 days then restart at half dose (given long t½) |
| Dose reduction in CYP2D6 poor metabolizers or with 2D6 inhibitors | Halve the dose |
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry
8. Clinical Drug Studies and Evidence Base
- FDA approval was based on 11 placebo-controlled studies (now 13 published, 7 positive, 6 failed)
- Doses studied: 1-20 mg/day over 6-8 weeks
- Included adult and one elderly cohort (Katona et al., mean age 71)
- One study (Wang et al., 2019) was retracted due to concerns about unauthorized use in China
Key comparator trials:
- Vortioxetine vs. duloxetine 60 mg/day (active comparator in 5 trials - 3 positive, 1 negative, 1 failed)
- Vortioxetine vs. venlafaxine XR 225 mg/day (positive)
- CONNECT study: Vortioxetine superior to agomelatine in SSRI/SNRI non-responders
- Noninferior to venlafaxine XR 150 mg in adults (8 weeks) and to sertraline 75 mg in elderly (6 weeks)
- Relapse prevention: Placebo-controlled randomized discontinuation study showed statistically significant delay in time to relapse; cumulative relapse rates 32.5% (placebo) vs. lower rates for all vortioxetine doses
Recent high-quality evidence:
- Yang et al., 2024 (PMID 38957929) - Systematic review and dose-response meta-analysis of RCTs confirms efficacy with dose-dependent effects
- Kishi et al., 2023 (PMID 36253442) - Network meta-analysis confirming maintenance efficacy of vortioxetine in MDD
COGNITIVE EFFECTS - Special Feature: Several trials demonstrated vortioxetine significantly improved objective cognitive performance (DSST - Digit Symbol Substitution Test) vs. placebo and vs. duloxetine, independent of mood improvement. This is a distinguishing feature not shared by most antidepressants.
9. Adverse Drug Reactions (ADRs)
Most common (dose-dependent):
- Nausea (most frequent, especially at initiation; dose-dependent)
- Vomiting
- Diarrhea
- Dry mouth
- Constipation
- Dizziness
- Sexual dysfunction (lower rate than SSRIs in some studies, but still present)
Switching from SSRI/SNRI with sexual dysfunction: An RCT switching patients with SSRI-induced sexual dysfunction to vortioxetine 10/20 mg vs. citalopram showed improvement in sexual function with vortioxetine.
Hematologic/Biochemical: No clinically significant changes in biochemical or hematologic parameters vs. placebo in studies.
Platelet function: Like SSRIs/SNRIs, vortioxetine inhibits SERT on platelets - monitor for increased bleeding risk, especially with NSAIDs, aspirin, or anticoagulants.
Serious adverse events: Five deaths were reported in short-term studies, but none attributable to vortioxetine itself.
What is notably ABSENT:
-
No significant weight gain
-
No significant sedation
-
No clinically relevant cardiac effects
-
No significant anticholinergic effects
-
Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Katzung's Basic and Clinical Pharmacology, 16th Ed.
10. Contraindications
- MAOIs: Do not use vortioxetine with MAOIs or within 21 days of stopping an MAOI; do not start an MAOI within 21 days of stopping vortioxetine (serotonin syndrome risk)
- Hypersensitivity to vortioxetine or excipients
11. Precautions and Warnings
- Black box warning (FDA): Increased risk of suicidal thoughts/behaviors in children, adolescents, and young adults (< 25 years) with antidepressants (class warning)
- Serotonin syndrome: Risk increases with combination of serotonergic agents (triptans, tramadol, lithium, linezolid, IV methylene blue, fentanyl)
- Hyponatremia: Risk of SIADH (lower than with SSRIs but exists, especially in elderly)
- Activation and mania: Monitor for mania/hypomania; use with caution in patients with bipolar disorder
- Seizures: Use with caution in patients with seizure disorders
- Bleeding: NSAIDs, aspirin, anticoagulants increase risk
- Cognitive/psychomotor impairment: Minimal, but patients should exercise caution until their individual response is known
12. Toxicity
- Overdose data: Generally low lethality; no specific antidote
- Serotonin syndrome is the primary toxicity concern with overdose or drug combinations (treat with supportive care, cyproheptadine, and benzodiazepines for agitation)
- Given the long t½ (~66 hours), side effects or toxicity effects may persist for several days
13. Abuse/Dependence Potential
Vortioxetine has no known abuse or dependence potential. It is not a scheduled substance.
14. Discontinuation Syndrome
The long terminal half-life (~66 hours) provides a built-in gradual taper effect, making discontinuation syndrome less common and less severe than with shorter-acting antidepressants like paroxetine or venlafaxine. That said, gradual tapering is still recommended rather than abrupt discontinuation to minimize any discontinuation symptoms (nausea, dizziness, irritability, paresthesias).
15. Drug Interactions
| Interaction | Effect | Management |
|---|---|---|
| Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) | ~2x increase in vortioxetine levels | Halve the vortioxetine dose |
| Strong CYP inducers (rifampin, carbamazepine, phenytoin) | Decrease in vortioxetine levels | May increase up to 3x original dose; adjust back within 14 days of stopping inducer |
| Strong CYP3A4/2C9 inhibitors | Possible further increase in levels | Use with caution |
| MAOIs | Serotonin syndrome | Contraindicated; 21-day washout required |
| Serotonergic agents (triptans, tramadol, linezolid, methylene blue) | Serotonin syndrome | Use with caution or avoid |
| NSAIDs / aspirin / anticoagulants | Increased bleeding risk | Monitor; consider GI protection |
| Alcohol | Increased CNS depression | Caution advised |
Key point: Vortioxetine does NOT significantly inhibit or induce CYP enzymes itself, so it has minimal effect on other drugs' metabolism.
16. Special Populations
| Population | Recommendation |
|---|---|
| Elderly (≥65 years) | No dose adjustment required; one dedicated elderly study (Katona et al.); noninferior to sertraline 75 mg. Greater risk of hyponatremia in elderly. |
| Pediatric | Not FDA-approved for use in children or adolescents; no evidence of efficacy in this age group |
| Pregnancy | Category C (animal data); risk/benefit decision. No published human breastfeeding data; animal data show excretion in milk - breastfeeding not recommended |
| Hepatic impairment | No dose adjustment required for mild-moderate; caution in severe impairment |
| Renal impairment | No dose adjustment required; caution in severe impairment |
| CYP2D6 poor metabolizers | Halve the dose (levels approximately double) |
17. Guidelines for Use
- First-line option for MDD in adults; considered particularly when cognitive symptoms are prominent
- Can be used as monotherapy or following SSRI/SNRI non-response
- Consider as a switch option for patients with SSRI-induced sexual dysfunction
- Minimum trial period: 4-6 weeks at adequate dose before assessing response
- Optimal dose: Aim for 20 mg/day where tolerated (highest SERT occupancy and evidence of greatest efficacy)
PART 2: KETAMINE and ESKETAMINE (Spravato)
1. Introduction and Background
Ketamine was originally synthesized in 1962 as a safer anesthetic alternative to phencyclidine (PCP). It received FDA approval in 1970 as a dissociative anesthetic.
The antidepressant discovery came when Trullas and Skolnick (1990) proposed that NMDA receptor antagonism might have antidepressant potential. Berman et al. (2000) conducted the first controlled human study showing a single IV ketamine infusion (0.5 mg/kg) produced antidepressant effects within 72 hours in MDD. Zarate et al. (2006) confirmed rapid onset (within 24 hours) in treatment-resistant MDD (TRD) and bipolar depression. This has been described as "the most significant development in the treatment of depression in the past 60 years".
Esketamine is the S-enantiomer of ketamine - it has 4x greater NMDA receptor affinity than R-ketamine. Developed as an intranasal formulation (Spravato), it received:
- FDA approval March 2019 for TRD (used with an oral antidepressant)
- FDA approval August 2020 for MDD with acute suicidal ideation or behavior (MDSI)
Racemic ketamine does NOT have an FDA indication for depression (it is used off-label).
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Maudsley Prescribing Guidelines, 15th Ed.
2. Chemistry
- Chemical name: 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
- Molecular formula: C13H16ClNO; Molecular weight: 237.72
- Structure: Arylcycloalkylamine; synthetic derivative of cyclohexanone
- Has an asymmetric carbon at C2 - exists as two enantiomers: (S)-ketamine (esketamine) and (R)-ketamine (arketamine)
- Supplied as white crystalline powder or clear liquid; soluble in water and lipids
3. Mechanism of Action (MOA)
Primary mechanism: Non-competitive/uncompetitive NMDA receptor antagonist (blocks the NMDA receptor open channel)
Proposed antidepressant mechanism (multiple competing theories):
- Disinhibition hypothesis (most widely accepted):
- Ketamine blocks NMDA receptors on GABAergic interneurons, which normally inhibit glutamatergic neurons
- This disinhibits glutamate release in the prefrontal cortex
- The cortical glutamate surge activates AMPA receptors
- AMPA receptor activation triggers downstream BDNF release and mTOR pathway activation
- This leads to rapid synaptogenesis and restoration of synaptic plasticity lost in depression
- Metabolite hypothesis:
- The metabolite (2R,6R)-hydroxynorketamine (HNK), derived from R-ketamine, may be the active antidepressant mediator
- Acts via AMPA receptor activation independent of NMDA blockade
- May explain antidepressant effects without dissociative side effects
- Phase I trials with (2R,6R)-HNK are complete; Phase II trials planned
-
Opioid receptor involvement: Some evidence that ketamine's rapid antidepressant effects require opioid receptor activity (controversial)
-
Other receptor actions: Ketamine also has activity at opioid receptors, sigma-1 receptors, muscarinic receptors, and voltage-gated sodium and calcium channels - all may contribute
Enantiomer comparison:
| S-ketamine (esketamine) | R-ketamine (arketamine) | |
|---|---|---|
| NMDA affinity | 4x greater | Lower |
| Antidepressant onset | Fast | Possibly greater/longer-lasting (animal data) |
| Dissociative effects | More prominent | Less prominent (animal data) |
| FDA-approved psychiatric use | Yes (Spravato) | No |
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Maudsley Prescribing Guidelines, 15th Ed.
4. Pharmacokinetics
| Parameter | Ketamine (racemic/IV) | Esketamine (intranasal) |
|---|---|---|
| Bioavailability by route | IV: 100%; IN: 8-45%; oral: 17-29%; IM: ~93% | IN: ~48% |
| Tmax | IV: ~3 min; IN: 10-20 min; oral: ~30 min | IN: 20-40 min |
| Plasma protein binding | 53.5% | Similar |
| Distribution t½ (alpha) | 2-4 minutes | - |
| Elimination t½ (beta) | 2-4 hours | ~5 hours for esketamine |
| Metabolism | Hepatic, mainly CYP3A4 and CYP2B6 | Same |
| Principal metabolite | Norketamine (active, ~1/3 potency) further metabolized to 18+ compounds including (2R,6R)-HNK | Noresketamine |
| Excretion | Urine (as metabolites); 17% first-pass effect | Urine |
Oral bioavailability is low due to extensive first-pass metabolism - which is why IV and IN routes are preferred for psychiatric use.
Esketamine is a weak inducer of CYP2B6 and CYP3A4; it is NOT a substrate of P-glycoprotein.
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Katzung's Basic and Clinical Pharmacology, 16th Ed.
5. Indications
Ketamine (racemic):
- FDA-approved: Anesthetic agent (sole agent for procedures not requiring skeletal muscle relaxation; induction agent; supplement to other anesthetics)
- Off-label: Treatment-resistant depression; suicidal ideation; chronic pain; CRPS; status epilepticus
- On WHO Essential Medicines List
Esketamine (Spravato - intranasal):
- FDA-approved (psychiatric):
- TRD in adults (with concurrent oral antidepressant) - approved March 2019
- MDD with acute suicidal ideation or behavior (MDSI) in adults - approved August 2020
6. Dosage and Formulation
Esketamine (Spravato) - FDA-Approved Dosing
| Phase | Dose | Frequency |
|---|---|---|
| Induction (weeks 1-4) | 56 mg or 84 mg intranasal | Twice weekly |
| Maintenance phase 1 (weeks 5-8) | 56 mg or 84 mg | Once weekly |
| Maintenance phase 2 (week 9+) | 56 mg or 84 mg | Every 1-2 weeks |
- Starting dose: 56 mg; can increase to 84 mg based on tolerability
- Must be administered in a REMS-certified healthcare setting
- Patient must be monitored for at least 2 hours post-administration before discharge
- Formulation: 28 mg/device nasal spray; each dose requires 2 (56 mg) or 3 (84 mg) devices
Ketamine (IV - off-label for TRD, per Maudsley Guidelines)
| Route | Dose | Infusion | Frequency |
|---|---|---|---|
| IV | 0.5 mg/kg (up to 1.0 mg/kg if no response) - Start at 0.25 mg/kg in elderly | Over 40 minutes | Induction: 1-2x/week; Maintenance: weekly, then every 2 weeks, then monthly |
| SC | 0.5 mg/kg (up to 1.0 mg/kg) | SC bolus | As per IV |
| IM | 0.5 mg/kg | IM bolus | As per IV |
| Oral/sublingual | Typically 1-3 mg/kg oral (highly variable) | - | Less frequent; may supplement IV maintenance |
-
Oral has very low and variable bioavailability; novel oral formulations under development
-
IV is considered the gold standard for off-label ketamine in TRD
-
Maudsley Prescribing Guidelines, 15th Ed.
7. Adverse Drug Reactions (ADRs)
At Antidepressant Doses
| Drug | Common ADRs |
|---|---|
| Ketamine | Dissociation, visual distortions, difficulty speaking, numbness, confusion, dizziness, faintness, drowsiness/sedation, euphoria, blurred vision, hypertension |
| Esketamine (IN) | Dissociation, dizziness, nausea, sedation, vertigo, hypoesthesia, anxiety, lethargy, increased blood pressure, vomiting, "feeling drunk" |
Serious ADRs (primarily at anesthetic doses but risk exists at psychiatric doses)
- Ketamine: Hemodynamic instability, emergence reactions, risk of respiratory depression, laryngospasm, pediatric neurotoxicity
- Esketamine: Sedation/dissociation (boxed warning), abuse/misuse potential (boxed warning), suicidality (boxed warning for antidepressants as a class)
Cardiovascular
- Both cause transient hypertension and tachycardia at antidepressant doses
- Rare: hypotension, bradycardia, arrhythmias, cardiac decompensation
- Monitor vital signs during and after every administration
- Pretreatment ECG recommended before initiating ketamine
Urological (long-term/high-dose)
- Ketamine-induced cystitis (primarily with recreational use): urinary pain, reduced bladder capacity, epithelial bladder barrier damage, ureter stenosis, kidney failure
- In therapeutic psychiatric use, this is a concern but has not been widely reported - ongoing monitoring warranted
Cognitive
-
Short-term cognitive impairment and dissociation during/after administration
-
Monitor using Ketamine Side Effect Tool (KSET) questionnaire
-
Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Maudsley Prescribing Guidelines, 15th Ed.
8. Contraindications
Esketamine (Spravato):
- Aneurysmal vascular disease (thoracic/abdominal aorta, intracranial, peripheral arterial)
- Arteriovenous malformation
- Intracerebral hemorrhage
- Hypersensitivity to esketamine, ketamine, or excipients
Ketamine:
- Conditions where hypertension would be hazardous (severe hypertension, heart failure)
- History of psychosis or schizophrenia (relative contraindication)
- Elevated ICP or intraocular pressure (ketamine increases ICP and IOP)
9. Boxed Warnings (Esketamine / Spravato)
- Risk of sedation and dissociation - must administer in medically supervised setting
- Potential for abuse and misuse - Schedule III controlled substance
- Available only through REMS (Risk Evaluation and Mitigation Strategy)
- Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants (class warning)
REMS requirements for esketamine:
- Only dispensed in certified healthcare settings
- Patient must receive drug on-site under supervision
- Patient must be monitored for at least 2 hours
- Patient must not drive or use machinery on day of administration
- Patients who show signs of psychosis during treatment should not receive further doses
10. Precautions
- Blood pressure: Esketamine can raise BP significantly (monitor before and after each dose; if baseline BP >170/110, carefully consider benefit vs. risk)
- Cognitive impairment: Do not drive or operate machinery on the day of administration
- Embryo-fetal toxicity: Additional FDA warning for esketamine
- History of psychosis or mania: Use with caution; ketamine can exacerbate psychotic symptoms
- Drug-seeking behavior/history of substance use disorder: Careful risk-benefit assessment
- Elevated ICP: Ketamine traditionally contraindicated in raised ICP (current evidence is mixed - may be acceptable in ventilated patients with controlled ICP)
- Pre-administration workup: Physical exam, blood pressure, FBC, LFTs, TFTs, ECG recommended
11. Abuse and Dependence
- Ketamine: Schedule III controlled substance (US Controlled Substances Act)
- Street names: "K," "Special K," "Vitamin K," "Cat Valium"
- Routes of abuse: injection, snorting, smoking (added to tobacco/marijuana), oral ingestion
- At abuse doses (50-100 mg approaching anesthetic doses), produces the "K-hole" - extreme dissociation, noncommunicativeness, lack of self-awareness, unresponsiveness
- 2015 data: ~3 million individuals (1.1% of those ≥12 years) had tried ketamine in their lifetime
- Repeated use causes tolerance and psychological dependence; psychological withdrawal symptoms on cessation
- Esketamine carries official boxed warning for abuse/misuse; REMS exists specifically to mitigate this risk
- The controlled clinical setting for esketamine administration is designed to prevent diversion
12. Toxicity
- Overdose: CNS depression, respiratory depression, cardiovascular compromise
- Emergence reactions: Hallucinations, delirium, vivid dreams (treated with benzodiazepines)
- Serotonin syndrome possible if combined with serotonergic drugs
- Laryngospasm - rare but clinician must be trained in advanced life support
- Accidental overdoses can occur in recreational use, potentially causing respiratory arrest
13. Discontinuation
- Ketamine/esketamine do not cause a classic antidepressant discontinuation syndrome
- Relapse of depression is the main concern upon stopping - antidepressant effects of a single infusion last only 3-7 days
- Psychological dependence is possible, particularly with repeated high-dose use
- No established tapering protocol; clinical judgment required
14. Drug Interactions
| Interaction | Effect | Management |
|---|---|---|
| CYP3A4/2B6 inhibitors | Increased ketamine/esketamine levels | Monitor closely |
| CYP3A4/2B6 inducers | Decreased levels | May require dose adjustment |
| Ketamine/esketamine (as CYP3A4 inducers) | Decrease levels of CYP3A4 substrates | Check interactions |
| Benzodiazepines and GABA agonists (e.g., barbiturates) | May attenuate or delay antidepressant response | Consider timing; use lowest dose necessary |
| Lamotrigine | May attenuate antidepressant response (decreases glutamate release) | Caution |
| Opioids / CNS depressants / alcohol | Profound sedation, respiratory depression, coma, death | Avoid combination or extreme caution; opioids also prolong recovery time |
| MAOIs | Hypertensive crisis risk | Use with extreme caution; monitor vital signs closely |
| Sympathomimetics / vasopressin | Potentiated cardiovascular effects | Monitor vitals closely; individualize dose |
| Theophylline / aminophylline | May lower seizure threshold | Use with extreme caution |
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Katzung's Basic and Clinical Pharmacology, 16th Ed.
15. Evidence-Based Trials
Key Historical Trials
- Berman et al. (2000) - First controlled human study; single IV ketamine 0.5 mg/kg showed antidepressant effect vs. saline within 72 hours in MDD
- Zarate et al. (2006) - Landmark RCT (crossover design); confirmed rapid onset within 24 hours in treatment-resistant MDD and bipolar depression
Pivotal Esketamine Registration Trials (TRANSFORM Program)
- TRANSFORM-1, -2, -3: Esketamine IN + oral antidepressant vs. placebo + oral antidepressant in TRD; showed significant reduction in MADRS scores
- SUSTAIN-1, -2: Long-term maintenance studies; demonstrated esketamine significantly delayed time to relapse vs. placebo in patients who responded to acute treatment
Recent High-Quality Evidence
- ESCAPE-TRD (Reif et al., 2023 - PMID 37792613) - NEJM landmark trial: Esketamine nasal spray vs. quetiapine XR as augmentation in TRD; esketamine was superior to quetiapine over 32 weeks - benefits built over time, challenging the "rapid-acting" label
- Janik et al., 2025 (PMID 40601310) - JAMA Psychiatry: First RCT of esketamine monotherapy in TRD; showed efficacy without required concurrent oral antidepressant
- Fountoulakis et al., 2025 (PMID 39876682) - PRISMA systematic review and meta-analysis in Am J Psychiatry confirming esketamine efficacy for depression
- Alnefeesi et al., 2022 (PMID 35688035) - Systematic review and meta-analysis of real-world ketamine effectiveness in TRD; confirmed robust response rates
- Smith-Apeldoorn et al., 2022 (PMID 36244360) - Lancet Psychiatry systematic review on maintenance ketamine; confirmed feasibility and safety of repeated dosing
16. Special Populations
| Population | Recommendation |
|---|---|
| Elderly | Titrate from lower doses (0.25 mg/kg IV); greater risk of cardiovascular effects and cognitive impairment; BP monitoring critical |
| Pediatric | Esketamine: boxed warning for increased suicidality in children/young adults; not approved for pediatric depression |
| Pregnancy | NOT recommended; animal studies show adverse neurodevelopmental effects and neurodegeneration; excreted in breast milk; not assigned FDA pregnancy category by FDA but avoid |
| Breastfeeding | Not recommended (animal data show excretion in milk) |
| Cardiovascular disease | Use with extreme caution; pre-treatment ECG essential; contraindicated in aneurysmal vascular disease, AVM, intracerebral hemorrhage |
| Substance use disorder history | Careful risk-benefit assessment; REMS helps mitigate diversion risk; avoid in active addiction if possible |
| Hepatic impairment | Metabolism via CYP3A4/2B6; impaired hepatic function may increase drug levels; use with caution and consider dose reduction |
| Elevated ICP | Traditionally contraindicated (ketamine raises ICP); use with caution in monitored settings if unavoidable |
| Psychosis/schizophrenia | Relative contraindication; ketamine can worsen psychotic symptoms |
| Hypertension | If BP >170/110 mmHg at baseline, carefully weigh risk vs. benefit before dosing |
17. Guidelines for Use
REMS (Spravato-specific):
- Only dispensed in REMS-certified healthcare settings
- Must not be taken home by patients
- Patient monitored for minimum 2 hours post-administration
- No driving or operating machinery on day of treatment
- Prescribers must be certified through the REMS program
Clinical guidelines incorporating ketamine/esketamine:
- Multiple recent treatment guidelines (APA, CANMAT, Maudsley, BAP) now include ketamine/esketamine in treatment algorithms for TRD
- Maudsley 15th Ed. recommends IV ketamine as gold standard route for off-label TRD; considers it broadly as effective as ECT
- A 2023 Maudsley note highlights that the term "rapid-acting antidepressant" may need reconsideration given ESCAPE-TRD results showing sustained benefit over 32 weeks
Pre-treatment workup (Maudsley Guidelines):
- Physical examination
- Baseline blood pressure measurement
- Full blood count (FBC)
- Liver function tests (LFTs)
- Thyroid function tests (TFTs)
- ECG
Monitoring during and after treatment:
- Vital signs (BP, HR) during and after every session
- Dissociation assessment (CADSS or KSET scale)
- Mental status for emergence of psychosis
- Observation for minimum 1 hour (ketamine off-label) to 2 hours (esketamine REMS requirement)
Quick Comparison: Vortioxetine vs. Ketamine/Esketamine
| Feature | Vortioxetine | Ketamine/Esketamine |
|---|---|---|
| Drug class | Multimodal serotonergic antidepressant | NMDA receptor antagonist / dissociative |
| MOA | SERT inhibition + 5-HT receptor modulation (5-HT1A agonist, 5-HT3/7 antagonist) | NMDA blockade → glutamate disinhibition → AMPA activation → synaptogenesis |
| Onset of action | 2-4 weeks (standard antidepressant timeline) | Hours to days (rapid) |
| Duration of effect | Sustained (while taking daily oral dose) | 3-7 days per infusion (maintenance dosing required) |
| FDA indication | MDD (adults) - oral daily | TRD + MDSI (adults) - intranasal, REMS-certified setting only |
| Route | Oral (once daily) | IV, IN, IM, SC, SL/oral |
| Schedule/control | Not scheduled | Schedule III (ketamine); REMS required (esketamine) |
| Major ADRs | Nausea, sexual dysfunction, bleeding risk | Dissociation, hypertension, sedation, abuse potential |
| Key contraindication | MAOIs; hypersensitivity | Aneurysmal vascular disease, intracerebral hemorrhage, severe uncontrolled hypertension |
| Special advantage | Procognitive effects; favorable sexual and metabolic profile | Rapid relief of severe depression; effective in TRD and suicidal ideation |
| Special concern | CYP2D6 drug interactions | Abuse potential; cardiovascular effects; dissociation; bladder toxicity with long-term use |
Sources cited:
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry
- Kaplan and Sadock's Synopsis of Psychiatry
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
- The Maudsley Prescribing Guidelines in Psychiatry, 15th Ed.
- PubMed: PMIDs 38957929, 36253442, 37792613, 40601310, 39876682, 35688035, 36244360That is the complete, evidence-based guide to both drugs. Here is a summary of what was covered:
What This Guide Covers
Vortioxetine (Trintellix)
- MOA: Multimodal - SERT inhibitor + 5-HT1A agonist + 5-HT3/7/1D antagonist + 5-HT1B partial agonist (with specific Ki values for each target)
- PK: 75% bioavailability, t½ 66 hours, CYP2D6 primary metabolism, 98-99% protein bound, no active metabolites, no CYP induction/inhibition
- Dosing: 5-20 mg/day oral; 20 mg/day is optimal (80% SERT occupancy)
- Special features: Procognitive effects (DSST), better sexual tolerability than SSRIs, low weight gain/sedation profile
- Drug interactions: Halve dose with CYP2D6 inhibitors; adjust with CYP inducers; 21-day MAOI washout
Ketamine/Esketamine (Spravato)
- MOA: NMDA receptor antagonism → GABAergic disinhibition → cortical glutamate surge → AMPA activation → BDNF/mTOR/synaptogenesis
- Esketamine: 4x greater NMDA affinity than R-ketamine; t½ ~5 hours; CYP3A4/2B6 metabolism
- Dosing: Esketamine IN 56-84 mg twice weekly (induction) then weekly; IV ketamine 0.5 mg/kg over 40 min (off-label gold standard)
- REMS: Esketamine ONLY in certified settings with 2-hour monitoring
- Key trials: ESCAPE-TRD (NEJM 2023) - superior to quetiapine; Janik et al. 2025 (JAMA Psychiatry) - monotherapy efficacy
- Abuse: Schedule III; "K-hole" at high doses; bladder toxicity with chronic use
This is a shared conversation. Sign in to Orris to start your own chat.